Illumina Announces Changes to Board of Directors
Rhea-AI Summary
Illumina (NASDAQ: ILMN) announced Board changes on April 2, 2026: Frances Arnold, Robert S. Epstein, and Gary S. Guthart will retire from the Board in connection with the company's upcoming annual meeting, and the Board has nominated David P. King for election as a director.
Chair Scott Gottlieb thanked the retiring directors for their service and said David King brings operating experience, public company board leadership, and regulatory insight across healthcare and life sciences to support Illumina's next phase of growth and genomics integration into medicine.
Positive
- Board nominated David P. King to join the Board
- David P. King adds operating and regulatory experience
Negative
- Board will see retirement of three directors at annual meeting
David P. King nominated to support next phase of growth and innovation;
Frances Arnold, Robert S. Epstein, and Gary S. Guthart to retire from the Board
"On behalf of the entire Board and management team, I want to thank Frances, Robert, and Gary for their exceptional service to Illumina," said Scott Gottlieb, MD, Chair of the Board. "Their sound judgment and steady commitment helped steer the company through a period of transformation. Additionally, we're pleased to nominate David King to the Board. Dave brings operating experience, public company board leadership, and regulatory insight forged across the healthcare and life sciences landscape. He has led complex organizations and advised companies at the intersection of innovation and patient care, translating technological advances into scalable, real-world applications that improve healthcare. With strong Board support, Illumina continues to lead the industry in advancing the integration of genomics into the practice of medicine."
About David P. King
David P. King has extensive experience in healthcare and life sciences, serving in executive and non-executive roles. Mr. King is the former Executive Chairman and CEO of Laboratory Corporation of America Holdings, and currently serves as a director and chair of both Privia Health and AmSurg Corporation, and as a director of Smith & Nephew. His board experience includes recent positions at several healthcare companies including ZimVie (2022-2025), VaxCare (2021-2025), and Health Channels. Before joining LabCorp in 2001, Mr. King was a partner at Hogan & Hartson LLP (now Hogan Lovells) where he was a key leader in the firm's healthcare fraud and abuse practice, representing healthcare companies in investigations and litigation.
About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.
Contacts
Investors:
Illumina Investor Relations
858-291-6421
IR@illumina.com
Media:
Christine Douglass
PR@illumina.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/illumina-announces-changes-to-board-of-directors-302732352.html
SOURCE Illumina, Inc.
FAQ
Who is nominated to Illumina's board in the April 2, 2026 announcement (ILMN)?
Which Illumina directors announced retirement ahead of the 2026 annual meeting (ILMN)?
How might David P. King's nomination affect Illumina's board dynamics (ILMN)?
When will the retiring Illumina directors step down from the Board (ILMN)?
Does Illumina say why directors Frances Arnold, Robert Epstein, and Gary Guthart are retiring (ILMN)?
